Advancing Gene Therapy for Glanzmann Thrombasthenia: Urgent Support Needed

To make donations online, visit the Medical College of Wisconsin’s website.

Where asked for “Gift Designation,” choose “Other,”

then write “Department of Pediatrics, Dr. David Wilcox Glanzmann Thrombasthenia Research” in the “Enter your designation below” box.

We are making meaningful progress in testing our clinical gene therapy vector for Glanzmann Thrombasthenia (GT), and early results are promising. This essential work is generating the preliminary data needed to move forward with our FDA pre-IND (pre-investigational new drug) application, an essential step toward launching the first-ever gene therapy clinical trial for GT.

The Medical College of Wisconsin has approved funding for gene therapy research in the 2024–2025 fiscal year. However, community donations are down significantly, creating a budget gap that could slow our momentum. We urgently need your support to continue advancing this potentially life-changing treatment.

If you believe in the future of gene therapy for Glanzmann Thrombasthenia, now is the time to act. Your donation directly supports the research pushing us closer to a cure.

Thank you for being part of this mission.

—David A. Wilcox, PhD